Avenir Wellness Solutions Past Earnings Performance
Past criteria checks 0/6
Avenir Wellness Solutions has been growing earnings at an average annual rate of 6.2%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 41.6% per year.
Key information
6.2%
Earnings growth rate
27.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 41.6% |
| Return on equity | n/a |
| Net Margin | -255.3% |
| Last Earnings Update | 30 Sep 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How Avenir Wellness Solutions makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 23 | 4 | -11 | 8 | 0 |
| 30 Jun 23 | 5 | -5 | 9 | 0 |
| 31 Mar 23 | 5 | -14 | 10 | 0 |
| 31 Dec 22 | 5 | -19 | 10 | 0 |
| 30 Sep 22 | 5 | -14 | 9 | 0 |
| 30 Jun 22 | 5 | -21 | 10 | 0 |
| 31 Mar 22 | 6 | -11 | 11 | -1 |
| 31 Dec 21 | 6 | -9 | 14 | 0 |
| 30 Sep 21 | 6 | -23 | 19 | 1 |
| 30 Jun 21 | 5 | -22 | 17 | 1 |
| 31 Mar 21 | 3 | -36 | 15 | 3 |
| 31 Dec 20 | 2 | -31 | 11 | 3 |
| 30 Sep 20 | 1 | -15 | 9 | 3 |
| 30 Jun 20 | 1 | -10 | 9 | 3 |
| 31 Mar 20 | 1 | -9 | 10 | 3 |
| 31 Dec 19 | 1 | -21 | 10 | 2 |
| 30 Sep 19 | 1 | -22 | 9 | 2 |
| 30 Jun 19 | 1 | -29 | 9 | 2 |
| 31 Mar 19 | 1 | -19 | 8 | 1 |
| 31 Dec 18 | 1 | -10 | 6 | 1 |
| 30 Sep 18 | 0 | -10 | 6 | 2 |
| 30 Jun 18 | 0 | -7 | 4 | 2 |
| 31 Mar 18 | 0 | -7 | 5 | 2 |
| 31 Dec 17 | 0 | -8 | 6 | 1 |
| 30 Sep 17 | 0 | -9 | 8 | 1 |
| 30 Jun 17 | 0 | -8 | 7 | 1 |
| 31 Mar 17 | 0 | -6 | 5 | 1 |
| 31 Dec 16 | 0 | -4 | 3 | 1 |
| 30 Sep 16 | 0 | -2 | 2 | 1 |
| 30 Jun 16 | 0 | -2 | 1 | 1 |
| 31 Mar 16 | 0 | -2 | 1 | 1 |
| 31 Dec 15 | 0 | -2 | 1 | 1 |
| 31 Dec 14 | 1 | -1 | 1 | 1 |
Quality Earnings: AVRW is currently unprofitable.
Growing Profit Margin: AVRW is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AVRW is unprofitable, but has reduced losses over the past 5 years at a rate of 6.2% per year.
Accelerating Growth: Unable to compare AVRW's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AVRW is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: AVRW's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.